GlassScriptPhysician profile
Joseph H Liput
NPI 1578581427
$2,926.28
in general payments reported to CMS, 2019-2025
39 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $250 · 2021: $19.69 · 2023: $262 · 2024: $432 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $261.06 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $254.26 | 2019-2020 | |
| Valeritas, INC. | $199.74 | 2019 | |
| Amgen INC. | $150.33 | 2019-2025 | Tavneos |
| Insulet Corporation | $145.56 | 2019-2024 | Omnipod |
| Fresenius USA Marketing, INC. | $134.15 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $131.82 | 2019-2024 | Ozempic |
| Mallinckrodt Enterprises LLC | $122.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $122.19 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $120.98 | 2024 | Amtagvi |
| Blueprint Medicines Corporation | $120.83 | 2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $117.99 | 2023 | Opdivo |
| Vifor Pharma, INC. | $108.18 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $104.59 | 2019-2025 | Jynarque |
| Sanofi-Aventis U.S. LLC | $85.05 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Liput listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.